{"product_id":"rhgh-fragment-176-191-10mg-vial","title":"rHGH Fragment 176–191 10mg vial","description":"\u003ch3\u003e\n\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003e                                    \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003eFOR HUMAN \u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003e\u003cstrong\u003eCONSUMPTION\u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003cp data-end=\"787\" data-start=\"324\"\u003e\u003cstrong\u003erHGH Fragment 176–191\u003c\/strong\u003e is a synthetic peptide corresponding to the C-terminus of human growth hormone. Unlike full-length GH, the 176–191 fragment \u003cstrong data-end=\"555\" data-start=\"503\"\u003edoes not activate the GH receptor or raise IGF-1\u003c\/strong\u003e. Preclinical work suggests \u003cstrong data-end=\"614\" data-start=\"583\"\u003eadipocyte-selective actions\u003c\/strong\u003e—enhancing lipolysis and inhibiting lipogenesis—without classical GH-like anabolic or diabetogenic effects. It is \u003cstrong data-end=\"744\" data-start=\"728\"\u003enot approved\u003c\/strong\u003e for any indication in major jurisdictions.\u003c\/p\u003e\n\u003chr data-end=\"792\" data-start=\"789\"\u003e\n\u003ch3 data-end=\"866\" data-start=\"794\"\u003eAdditional Benefits of rHGH Fragment 176–191 Now Under Investigation\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"3078\" data-start=\"868\"\u003e\n\u003cthead data-end=\"896\" data-start=\"868\"\u003e\n\u003ctr data-end=\"896\" data-start=\"868\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"878\" data-start=\"868\"\u003eBenefit\u003c\/th\u003e\n\u003cth data-col-size=\"xl\" data-end=\"896\" data-start=\"878\"\u003eKey take-aways\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"3078\" data-start=\"907\"\u003e\n\u003ctr data-end=\"1178\" data-start=\"907\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"943\" data-start=\"907\"\u003e\u003cstrong data-end=\"942\" data-start=\"909\"\u003e1 Selective adipose lipolysis\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1178\" data-start=\"943\"\u003eRodent and cell studies show \u003cstrong data-end=\"1021\" data-start=\"974\"\u003eincreased hormone-sensitive lipase activity\u003c\/strong\u003e and glycerol\/FFA release in white adipocytes, with \u003cstrong data-end=\"1125\" data-start=\"1073\"\u003epreferential reduction of abdominal\/visceral fat\u003c\/strong\u003e versus lean tissue. \u0026lt;br\/\u0026gt;\u003cem data-end=\"1176\" data-start=\"1151\"\u003eEndocrinology; Peptides\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1404\" data-start=\"1179\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"1210\" data-start=\"1179\"\u003e\u003cstrong data-end=\"1209\" data-start=\"1181\"\u003e2 Anti-lipogenic effects\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1404\" data-start=\"1210\"\u003eDownstream signalling reduces \u003cstrong data-end=\"1265\" data-start=\"1242\"\u003ede novo lipogenesis\u003c\/strong\u003e markers (e.g., FAS\/ACC) and can blunt \u003cstrong data-end=\"1333\" data-start=\"1304\"\u003eLPL-mediated lipid uptake\u003c\/strong\u003e in adipose tissue. \u0026lt;br\/\u0026gt;\u003cem data-end=\"1402\" data-start=\"1358\"\u003eMetabolism; American Journal of Physiology\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1647\" data-start=\"1405\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"1440\" data-start=\"1405\"\u003e\u003cstrong data-end=\"1439\" data-start=\"1407\"\u003e3 Energy-expenditure signals\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1647\" data-start=\"1440\"\u003eIn diet-induced obese mice, treatment increases \u003cstrong data-end=\"1516\" data-start=\"1490\"\u003eUCP-1\/UCP-3 expression\u003c\/strong\u003e and fatty-acid oxidation genes, hinting at \u003cstrong data-end=\"1584\" data-start=\"1560\"\u003ebrowning\/thermogenic\u003c\/strong\u003e shifts. \u0026lt;br\/\u0026gt;\u003cem data-end=\"1645\" data-start=\"1598\"\u003eMolecular and Cellular Endocrinology; Obesity\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1863\" data-start=\"1648\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"1688\" data-start=\"1648\"\u003e\u003cstrong data-end=\"1687\" data-start=\"1650\"\u003e4 Glucose neutrality (short-term)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1863\" data-start=\"1688\"\u003eSmall human studies report \u003cstrong data-end=\"1769\" data-start=\"1717\"\u003eno meaningful change in fasting glucose or HbA1c\u003c\/strong\u003e over weeks; insulin and IGF-1 remain near baseline. \u0026lt;br\/\u0026gt;\u003cem data-end=\"1861\" data-start=\"1827\"\u003eDiabetes, Obesity and Metabolism\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2098\" data-start=\"1864\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"1891\" data-start=\"1864\"\u003e\u003cstrong data-end=\"1890\" data-start=\"1866\"\u003e5 No IGF-1 elevation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2098\" data-start=\"1891\"\u003eBecause the fragment lacks GH-receptor activity, \u003cstrong data-end=\"1980\" data-start=\"1942\"\u003eIGF-1 levels typically do not rise\u003c\/strong\u003e, potentially lowering mitogenic and edema risks seen with GH. \u0026lt;br\/\u0026gt;\u003cem data-end=\"2096\" data-start=\"2048\"\u003eJournal of Clinical Endocrinology \u0026amp; Metabolism\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2357\" data-start=\"2099\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"2139\" data-start=\"2099\"\u003e\u003cstrong data-end=\"2138\" data-start=\"2101\"\u003e6 Joint\/tendon exploratory signal\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2357\" data-start=\"2139\"\u003ePreclinical work shows \u003cstrong data-end=\"2202\" data-start=\"2164\"\u003eincreased collagen gene expression\u003c\/strong\u003e and improved histology after tendon injury; human data are \u003cstrong data-end=\"2278\" data-start=\"2262\"\u003einsufficient\u003c\/strong\u003e. \u0026lt;br\/\u0026gt;\u003cem data-end=\"2355\" data-start=\"2285\"\u003eJournal of Orthopaedic Research; American Journal of Sports Medicine\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2592\" data-start=\"2358\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"2387\" data-start=\"2358\"\u003e\u003cstrong data-end=\"2386\" data-start=\"2360\"\u003e7 Liver-fat hypothesis\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2592\" data-start=\"2387\"\u003eBy reducing ectopic lipid flux from adipose tissue, models suggest \u003cstrong data-end=\"2498\" data-start=\"2456\"\u003edownward pressure on hepatic steatosis\u003c\/strong\u003e; \u003cstrong data-end=\"2541\" data-start=\"2500\"\u003econfirmatory human trials are lacking\u003c\/strong\u003e. \u0026lt;br\/\u0026gt;\u003cem data-end=\"2590\" data-start=\"2548\"\u003eHepatology; Lipids in Health and Disease\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2825\" data-start=\"2593\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"2619\" data-start=\"2593\"\u003e\u003cstrong data-end=\"2618\" data-start=\"2595\"\u003e8 Lifestyle synergy\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2825\" data-start=\"2619\"\u003ePairing with \u003cstrong data-end=\"2670\" data-start=\"2634\"\u003ecaloric restriction and exercise\u003c\/strong\u003e amplifies fat-loss signals in animal models; human trials to date \u003cstrong data-end=\"2782\" data-start=\"2737\"\u003edid not show large standalone weight loss\u003c\/strong\u003e. \u0026lt;br\/\u0026gt;\u003cem data-end=\"2823\" data-start=\"2789\"\u003eInternational Journal of Obesity\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3078\" data-start=\"2826\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"2847\" data-start=\"2826\"\u003e\u003cstrong data-end=\"2846\" data-start=\"2828\"\u003e9 Tolerability\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"3078\" data-start=\"2847\"\u003eAcross short-term studies, \u003cstrong data-end=\"2901\" data-start=\"2876\"\u003eAE rates near placebo\u003c\/strong\u003e (GI upset, headache most common); no consistent edema, arthralgia, or IGF-1-related effects. Long-term safety remains \u003cstrong data-end=\"3033\" data-start=\"3020\"\u003euncertain\u003c\/strong\u003e. \u0026lt;br\/\u0026gt;\u003cem data-end=\"3076\" data-start=\"3040\"\u003eDrug Safety; Clinical Therapeutics\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"3083\" data-start=\"3080\"\u003e\n\u003ch2 data-end=\"3120\" data-start=\"3085\"\u003e2. Molecular Mechanism of Action\u003c\/h2\u003e\n\u003ch3 data-end=\"3157\" data-start=\"3122\"\u003e2.1 Receptor Pharmacodynamics\u003c\/h3\u003e\n\u003cp data-end=\"3471\" data-start=\"3158\"\u003eThe 176–191 fragment \u003cstrong data-end=\"3224\" data-start=\"3179\"\u003edoes not bind or activate the GH receptor\u003c\/strong\u003e and \u003cstrong data-end=\"3257\" data-start=\"3229\"\u003edoes not stimulate IGF-1\u003c\/strong\u003e. Proposed actions are \u003cstrong data-end=\"3303\" data-start=\"3280\"\u003eadipocyte-selective\u003c\/strong\u003e, with evidence for \u003cstrong data-end=\"3339\" data-start=\"3323\"\u003ecAMP\/PKA-HSL\u003c\/strong\u003e pathway activation and \u003cstrong data-end=\"3416\" data-start=\"3363\"\u003esuppression of lipogenic transcriptional programs\u003c\/strong\u003e. The precise upstream receptor remains \u003cstrong data-end=\"3470\" data-start=\"3456\"\u003eunresolved\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch3 data-end=\"3500\" data-start=\"3473\"\u003e2.2 Down-stream Biology\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"3816\" data-start=\"3502\"\u003e\n\u003cthead data-end=\"3544\" data-start=\"3502\"\u003e\n\u003ctr data-end=\"3544\" data-start=\"3502\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"3512\" data-start=\"3502\"\u003ePathway\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"3533\" data-start=\"3512\"\u003eFunctional outcome\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"3544\" data-start=\"3533\"\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"3816\" data-start=\"3559\"\u003e\n\u003ctr data-end=\"3630\" data-start=\"3559\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3574\" data-start=\"3559\"\u003ecAMP–PKA–HSL\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3606\" data-start=\"3574\"\u003e↑ lipolysis, FFA mobilization\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3630\" data-start=\"3606\"\u003eWhite adipose tissue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3711\" data-start=\"3631\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3654\" data-start=\"3631\"\u003eAMPK\/PPAR cross-talk\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3694\" data-start=\"3654\"\u003e↑ fatty-acid oxidation, ↓ lipogenesis\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3711\" data-start=\"3694\"\u003eLiver\/adipose\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3816\" data-start=\"3712\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3753\" data-start=\"3712\"\u003eMitochondrial\/thermogenic genes (UCPs)\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3790\" data-start=\"3753\"\u003e↑ energy expenditure (preclinical)\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3816\" data-start=\"3790\"\u003eBrown\/brite adipocytes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"3821\" data-start=\"3818\"\u003e\n\u003ch2 data-end=\"3845\" data-start=\"3823\"\u003e3. Pharmacokinetics\u003c\/h2\u003e\n\u003cul data-end=\"4347\" data-start=\"3847\"\u003e\n\u003cli data-end=\"4026\" data-start=\"3847\"\u003e\n\u003cp data-end=\"4026\" data-start=\"3849\"\u003e\u003cstrong data-end=\"3870\" data-start=\"3849\"\u003eAbsorption\/route:\u003c\/strong\u003e Investigated as \u003cstrong data-end=\"3909\" data-start=\"3887\"\u003eparenteral peptide\u003c\/strong\u003e; some programs explored \u003cstrong data-end=\"3955\" data-start=\"3934\"\u003eoral formulations\u003c\/strong\u003e, but \u003cstrong data-end=\"3997\" data-start=\"3961\"\u003eoral bioavailability appears low\u003c\/strong\u003e and formulation-dependent.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4196\" data-start=\"4027\"\u003e\n\u003cp data-end=\"4196\" data-start=\"4029\"\u003e\u003cstrong data-end=\"4043\" data-start=\"4029\"\u003eHalf-life:\u003c\/strong\u003e \u003cstrong data-end=\"4088\" data-start=\"4044\"\u003eShort plasma half-life (minutes to ~1 h)\u003c\/strong\u003e typical of small peptides; pharmacodynamic effects depend on \u003cstrong data-end=\"4169\" data-start=\"4150\"\u003efrequent dosing\u003c\/strong\u003e or specialized delivery.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4347\" data-start=\"4197\"\u003e\n\u003cp data-end=\"4347\" data-start=\"4199\"\u003e\u003cstrong data-end=\"4226\" data-start=\"4199\"\u003eDistribution\/Clearance:\u003c\/strong\u003e Primarily extracellular distribution; \u003cstrong data-end=\"4292\" data-start=\"4265\"\u003eproteolytic degradation\u003c\/strong\u003e and renal clearance; \u003cstrong data-end=\"4324\" data-start=\"4314\"\u003eno CYP\u003c\/strong\u003e interactions expected.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"4352\" data-start=\"4349\"\u003e\n\u003ch2 data-end=\"4399\" data-start=\"4354\"\u003e4. Pre-clinical and Translational Evidence\u003c\/h2\u003e\n\u003ch3 data-end=\"4428\" data-start=\"4401\"\u003e4.1 Obesity\/Adiposity\u003c\/h3\u003e\n\u003cp data-end=\"4696\" data-start=\"4429\"\u003eMultiple rodent studies show \u003cstrong data-end=\"4520\" data-start=\"4458\"\u003ereductions in fat mass and improvements in lipid oxidation\u003c\/strong\u003e with minimal effect on lean mass. \u003cstrong data-end=\"4585\" data-start=\"4555\"\u003eHuman RCTs have been mixed\u003c\/strong\u003e and \u003cstrong data-end=\"4646\" data-start=\"4590\"\u003eseveral failed to meet primary weight-loss endpoints\u003c\/strong\u003e, though \u003cstrong data-end=\"4671\" data-start=\"4655\"\u003etolerability\u003c\/strong\u003ewas generally favorable.\u003c\/p\u003e\n\u003ch3 data-end=\"4724\" data-start=\"4698\"\u003e4.2 Metabolic Health\u003c\/h3\u003e\n\u003cp data-end=\"4924\" data-start=\"4725\"\u003eShort-term human data show \u003cstrong data-end=\"4773\" data-start=\"4752\"\u003eneutral glycaemia\u003c\/strong\u003e and \u003cstrong data-end=\"4795\" data-start=\"4778\"\u003eno IGF-1 rise\u003c\/strong\u003e; lipid changes are modest and inconsistent. In animals, \u003cstrong data-end=\"4878\" data-start=\"4852\"\u003ehepatic lipid handling\u003c\/strong\u003e and \u003cstrong data-end=\"4914\" data-start=\"4883\"\u003ethermogenic gene expression\u003c\/strong\u003e improved.\u003c\/p\u003e\n\u003ch3 data-end=\"4958\" data-start=\"4926\"\u003e4.3 Musculoskeletal Tissue\u003c\/h3\u003e\n\u003cp data-end=\"5106\" data-start=\"4959\"\u003eExploratory preclinical data suggest \u003cstrong data-end=\"5018\" data-start=\"4996\"\u003ecollagen synthesis\u003c\/strong\u003e support and improved histology after tendon injury; \u003cstrong data-end=\"5105\" data-start=\"5071\"\u003eclinical relevance is unproven\u003c\/strong\u003e.\u003c\/p\u003e\n\u003chr data-end=\"5111\" data-start=\"5108\"\u003e\n\u003ch2 data-end=\"5146\" data-start=\"5113\"\u003e5. Emerging Clinical Interests\u003c\/h2\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"5638\" data-start=\"5148\"\u003e\n\u003cthead data-end=\"5186\" data-start=\"5148\"\u003e\n\u003ctr data-end=\"5186\" data-start=\"5148\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"5156\" data-start=\"5148\"\u003eField\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"5168\" data-start=\"5156\"\u003eRationale\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"5186\" data-start=\"5168\"\u003eCurrent status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"5638\" data-start=\"5201\"\u003e\n\u003ctr data-end=\"5318\" data-start=\"5201\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5231\" data-start=\"5201\"\u003e\u003cstrong data-end=\"5230\" data-start=\"5203\"\u003eAdjunct in obesity care\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5277\" data-start=\"5231\"\u003eAdipocyte-selective lipolysis without IGF-1\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5318\" data-start=\"5277\"\u003eEarly human signals; \u003cstrong data-end=\"5316\" data-start=\"5300\"\u003eno approvals\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5441\" data-start=\"5319\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5350\" data-start=\"5319\"\u003e\u003cstrong data-end=\"5349\" data-start=\"5321\"\u003eNAFLD\/MASH (theoretical)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5393\" data-start=\"5350\"\u003eReduced adipose lipid spillover to liver\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5441\" data-start=\"5393\"\u003ePreclinical rationale; \u003cstrong data-end=\"5439\" data-start=\"5418\"\u003eno pivotal trials\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5531\" data-start=\"5442\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5471\" data-start=\"5442\"\u003e\u003cstrong data-end=\"5470\" data-start=\"5444\"\u003eSports-injury recovery\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5511\" data-start=\"5471\"\u003eCollagen gene up-regulation in models\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5531\" data-start=\"5511\"\u003ePreclinical only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5638\" data-start=\"5532\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5559\" data-start=\"5532\"\u003e\u003cstrong data-end=\"5558\" data-start=\"5534\"\u003eCardiometabolic risk\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5608\" data-start=\"5559\"\u003ePossible TG\/HDL improvements if fat mass drops\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5638\" data-start=\"5608\"\u003eRequires robust human data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"5643\" data-start=\"5640\"\u003e\n\u003ch2 data-end=\"5674\" data-start=\"5645\"\u003e6. Safety and Tolerability\u003c\/h2\u003e\n\u003cul data-end=\"6088\" data-start=\"5676\"\u003e\n\u003cli data-end=\"5772\" data-start=\"5676\"\u003e\n\u003cp data-end=\"5772\" data-start=\"5678\"\u003e\u003cstrong data-end=\"5693\" data-start=\"5678\"\u003eCommon AEs:\u003c\/strong\u003e Mild \u003cstrong data-end=\"5716\" data-start=\"5699\"\u003eGI discomfort\u003c\/strong\u003e, \u003cstrong data-end=\"5730\" data-start=\"5718\"\u003eheadache\u003c\/strong\u003e, injection-site reactions (parenteral).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5879\" data-start=\"5773\"\u003e\n\u003cp data-end=\"5879\" data-start=\"5775\"\u003e\u003cstrong data-end=\"5789\" data-start=\"5775\"\u003eEndocrine:\u003c\/strong\u003e \u003cstrong data-end=\"5809\" data-start=\"5790\"\u003eIGF-1 unchanged\u003c\/strong\u003e; \u003cstrong data-end=\"5850\" data-start=\"5811\"\u003eno GH-like edema\/arthralgia pattern\u003c\/strong\u003e reported in short studies.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5957\" data-start=\"5880\"\u003e\n\u003cp data-end=\"5957\" data-start=\"5882\"\u003e\u003cstrong data-end=\"5896\" data-start=\"5882\"\u003eGlycaemia:\u003c\/strong\u003e Generally \u003cstrong data-end=\"5918\" data-start=\"5907\"\u003eneutral\u003c\/strong\u003e; no systematic hypoglycaemia signal.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6088\" data-start=\"5958\"\u003e\n\u003cp data-end=\"6088\" data-start=\"5960\"\u003e\u003cstrong data-end=\"5973\" data-start=\"5960\"\u003eUnknowns:\u003c\/strong\u003e \u003cstrong data-end=\"5994\" data-start=\"5974\"\u003eLong-term safety\u003c\/strong\u003e, carcinogenicity, and effects in special populations remain \u003cstrong data-end=\"6087\" data-start=\"6055\"\u003einsufficiently characterized\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"6119\" data-start=\"6090\"\u003e\u003cstrong data-end=\"6119\" data-start=\"6090\"\u003eComparative safety matrix\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"6553\" data-start=\"6121\"\u003e\n\u003cthead data-end=\"6202\" data-start=\"6121\"\u003e\n\u003ctr data-end=\"6202\" data-start=\"6121\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"6131\" data-start=\"6121\"\u003eConcern\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"6155\" data-start=\"6131\"\u003erHGH 176–191 fragment\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"6183\" data-start=\"6155\"\u003eTesamorelin (GHRH analog)\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"6202\" data-start=\"6183\"\u003eSomatropin (GH)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"6553\" data-start=\"6221\"\u003e\n\u003ctr data-end=\"6300\" data-start=\"6221\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6239\" data-start=\"6221\"\u003eIGF-1 elevation\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6248\" data-start=\"6239\"\u003e\u003cstrong data-end=\"6247\" data-start=\"6241\"\u003eNo\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6272\" data-start=\"6248\"\u003e\u003cstrong data-end=\"6271\" data-start=\"6250\"\u003eYes (physiologic)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6300\" data-start=\"6272\"\u003e\u003cstrong data-end=\"6298\" data-start=\"6274\"\u003eYes (dose-dependent)\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"6373\" data-start=\"6301\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6320\" data-start=\"6301\"\u003eEdema\/arthralgia\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6343\" data-start=\"6320\"\u003e\u003cstrong data-end=\"6342\" data-start=\"6322\"\u003eLow (short-term)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6354\" data-start=\"6343\"\u003eModerate\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6373\" data-start=\"6354\"\u003eModerate–higher\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"6455\" data-start=\"6374\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6393\" data-start=\"6374\"\u003eGlycaemic impact\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6416\" data-start=\"6393\"\u003eNeutral (short-term)\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6435\" data-start=\"6416\"\u003eNeutral → mild ↑\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6455\" data-start=\"6435\"\u003eNeutral → mild ↑\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"6553\" data-start=\"6456\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6480\" data-start=\"6456\"\u003eEvidence for fat loss\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6506\" data-start=\"6480\"\u003e\u003cstrong data-end=\"6505\" data-start=\"6482\"\u003ePreclinical \u0026gt; human\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6526\" data-start=\"6506\"\u003eRobust in HIV VAT\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6553\" data-start=\"6526\"\u003eMixed in non-GHD adults\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"6558\" data-start=\"6555\"\u003e\n\u003ch2 data-end=\"6586\" data-start=\"6560\"\u003e7. Regulatory Landscape\u003c\/h2\u003e\n\u003cul data-end=\"6932\" data-start=\"6588\"\u003e\n\u003cli data-end=\"6686\" data-start=\"6588\"\u003e\n\u003cp data-end=\"6686\" data-start=\"6590\"\u003e\u003cstrong data-end=\"6610\" data-start=\"6590\"\u003eApproval status:\u003c\/strong\u003e \u003cstrong data-end=\"6627\" data-start=\"6611\"\u003eNot approved\u003c\/strong\u003e by FDA\/EMA or other major regulators for any indication.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6816\" data-start=\"6687\"\u003e\n\u003cp data-end=\"6816\" data-start=\"6689\"\u003e\u003cstrong data-end=\"6709\" data-start=\"6689\"\u003eSporting bodies:\u003c\/strong\u003e Classified under \u003cstrong data-end=\"6754\" data-start=\"6727\"\u003enon-approved substances\u003c\/strong\u003e by anti-doping authorities; use in sport is \u003cstrong data-end=\"6813\" data-start=\"6799\"\u003eprohibited\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6932\" data-start=\"6817\"\u003e\n\u003cp data-end=\"6932\" data-start=\"6819\"\u003e\u003cstrong data-end=\"6830\" data-start=\"6819\"\u003eSupply:\u003c\/strong\u003e Frequently marketed online as a \u003cstrong data-end=\"6886\" data-start=\"6863\"\u003e“research chemical”\u003c\/strong\u003e; quality, purity, and dosing \u003cstrong data-end=\"6931\" data-start=\"6916\"\u003enot assured\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"6937\" data-start=\"6934\"\u003e\n\u003ch2 data-end=\"6962\" data-start=\"6939\"\u003e8. Future Directions\u003c\/h2\u003e\n\u003cul data-end=\"7476\" data-start=\"6964\"\u003e\n\u003cli data-end=\"7082\" data-start=\"6964\"\u003e\n\u003cp data-end=\"7082\" data-start=\"6966\"\u003e\u003cstrong data-end=\"6990\" data-start=\"6966\"\u003eMechanistic clarity:\u003c\/strong\u003e Identify the \u003cstrong data-end=\"7032\" data-start=\"7004\"\u003eproximal receptor\/target\u003c\/strong\u003e and confirm \u003cstrong data-end=\"7069\" data-start=\"7045\"\u003eon-target biomarkers\u003c\/strong\u003e in humans.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7199\" data-start=\"7083\"\u003e\n\u003cp data-end=\"7199\" data-start=\"7085\"\u003e\u003cstrong data-end=\"7104\" data-start=\"7085\"\u003ePK engineering:\u003c\/strong\u003e \u003cstrong data-end=\"7128\" data-start=\"7105\"\u003eHalf-life extension\u003c\/strong\u003e (e.g., lipidation, depot, or pegylation) to enable practical dosing.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7333\" data-start=\"7200\"\u003e\n\u003cp data-end=\"7333\" data-start=\"7202\"\u003e\u003cstrong data-end=\"7226\" data-start=\"7202\"\u003ePhenotype targeting:\u003c\/strong\u003e Trials in \u003cstrong data-end=\"7269\" data-start=\"7237\"\u003evisceral-predominant obesity\u003c\/strong\u003e or \u003cstrong data-end=\"7282\" data-start=\"7273\"\u003eNAFLD\u003c\/strong\u003e with imaging (MRI-PDFF) and metabolic endpoints.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7476\" data-start=\"7334\"\u003e\n\u003cp data-end=\"7476\" data-start=\"7336\"\u003e\u003cstrong data-end=\"7360\" data-start=\"7336\"\u003eCombination therapy:\u003c\/strong\u003e Pairing with \u003cstrong data-end=\"7396\" data-start=\"7374\"\u003eGLP-1\/GIP agonists\u003c\/strong\u003e or \u003cstrong data-end=\"7420\" data-start=\"7400\"\u003eSGLT2 inhibitors\u003c\/strong\u003e to evaluate \u003cstrong data-end=\"7475\" data-start=\"7433\"\u003eadditive fat- and liver-fat reductions\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"7481\" data-start=\"7478\"\u003e\n\u003ch3 data-end=\"7506\" data-start=\"7483\"\u003eSelected References\u003c\/h3\u003e\n\u003cul data-end=\"8214\" data-start=\"7508\"\u003e\n\u003cli data-end=\"7683\" data-start=\"7508\"\u003e\n\u003cp data-end=\"7683\" data-start=\"7510\"\u003e\u003cstrong data-end=\"7581\" data-start=\"7510\"\u003eEndocrinology; Peptides; Metabolism; American Journal of Physiology\u003c\/strong\u003e — preclinical studies of hGH C-terminal fragments (176–191) on adipocyte lipolysis and lipogenesis.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7853\" data-start=\"7684\"\u003e\n\u003cp data-end=\"7853\" data-start=\"7686\"\u003e\u003cstrong data-end=\"7754\" data-start=\"7686\"\u003eObesity; Diabetes, Obesity and Metabolism; Clinical Therapeutics\u003c\/strong\u003e — human tolerability and efficacy signals; several trials with \u003cstrong data-end=\"7850\" data-start=\"7818\"\u003elimited weight-loss outcomes\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8002\" data-start=\"7854\"\u003e\n\u003cp data-end=\"8002\" data-start=\"7856\"\u003e\u003cstrong data-end=\"7928\" data-start=\"7856\"\u003eJournal of Orthopaedic Research; American Journal of Sports Medicine\u003c\/strong\u003e — exploratory musculoskeletal\/tendon biology with GH-fragment peptides.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8095\" data-start=\"8003\"\u003e\n\u003cp data-end=\"8095\" data-start=\"8005\"\u003e\u003cstrong data-end=\"8020\" data-start=\"8005\"\u003eDrug Safety\u003c\/strong\u003e — short-term safety summaries for peptide-based anti-obesity candidates.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8214\" data-start=\"8096\"\u003e\n\u003cp data-end=\"8214\" data-start=\"8098\"\u003e\u003cstrong data-end=\"8140\" data-start=\"8098\"\u003eWorld Anti-Doping Code\/Prohibited List\u003c\/strong\u003e — classification of non-approved peptide hormones and related substance\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":52684855443794,"sku":null,"price":50.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/rHGH_Fragment_176_191_10mg.png?v=1770834876","url":"https:\/\/sciencepeptideslab.com\/products\/rhgh-fragment-176-191-10mg-vial","provider":"Science Peptides Lab","version":"1.0","type":"link"}